JP2005508338A - 免疫性疾患を処置するためのガンマグロブリンの使用 - Google Patents

免疫性疾患を処置するためのガンマグロブリンの使用 Download PDF

Info

Publication number
JP2005508338A
JP2005508338A JP2003532004A JP2003532004A JP2005508338A JP 2005508338 A JP2005508338 A JP 2005508338A JP 2003532004 A JP2003532004 A JP 2003532004A JP 2003532004 A JP2003532004 A JP 2003532004A JP 2005508338 A JP2005508338 A JP 2005508338A
Authority
JP
Japan
Prior art keywords
immunoglobulin
route
disease
subject
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003532004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508338A5 (enExample
Inventor
バーストウ、レオン、イー．
ワイスバート、リチャード
オストリム、ジェイムズ、エイ．
エンリケス、エフ．、ジェイヴィア
Original Assignee
プロテイン セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロテイン セラピューティクス、インク． filed Critical プロテイン セラピューティクス、インク．
Publication of JP2005508338A publication Critical patent/JP2005508338A/ja
Publication of JP2005508338A5 publication Critical patent/JP2005508338A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003532004A 2001-10-04 2002-10-04 免疫性疾患を処置するためのガンマグロブリンの使用 Pending JP2005508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32704301P 2001-10-04 2001-10-04
US38096002P 2002-05-16 2002-05-16
PCT/US2002/033322 WO2003028668A2 (en) 2001-10-04 2002-10-04 Gammaglobulin treatment of immune disorders

Publications (2)

Publication Number Publication Date
JP2005508338A true JP2005508338A (ja) 2005-03-31
JP2005508338A5 JP2005508338A5 (enExample) 2006-01-05

Family

ID=26985697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532004A Pending JP2005508338A (ja) 2001-10-04 2002-10-04 免疫性疾患を処置するためのガンマグロブリンの使用

Country Status (6)

Country Link
US (1) US20030099635A1 (enExample)
EP (1) EP1463527A4 (enExample)
JP (1) JP2005508338A (enExample)
CA (1) CA2462682A1 (enExample)
MX (1) MXPA04003156A (enExample)
WO (1) WO2003028668A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520387A (ja) * 2017-05-18 2020-07-09 アーペーセー エウローペ ソシエダッド リミタダ ウニペルソナル ヒト及びコンパニオン動物の認知欠損障害の治療に使用するための動物血漿又はその画分

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222141A1 (en) * 2002-03-29 2003-10-13 Repligen Corporation Ctla4 compositions in the treatment of autism
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014911A2 (en) * 2004-07-26 2006-02-09 Kossor David C Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US20060205012A1 (en) 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
ES2477294T3 (es) 2007-08-13 2014-07-16 Baxter International Inc Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US20130034541A1 (en) * 2010-04-23 2013-02-07 Probiotec Limited Pharmaceutical compositions
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
DK2961426T3 (da) 2013-02-26 2019-12-02 Baxalta GmbH Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
LT2994160T (lt) 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
WO1998052593A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
CA2331738A1 (en) * 1998-05-07 1999-11-11 Research Corporation Technologies, Inc. Oral administration of immunoglobulins for treating autoimmune hearing loss
JP2002523035A (ja) * 1998-08-25 2002-07-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
WO2000062806A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520387A (ja) * 2017-05-18 2020-07-09 アーペーセー エウローペ ソシエダッド リミタダ ウニペルソナル ヒト及びコンパニオン動物の認知欠損障害の治療に使用するための動物血漿又はその画分
JP7312163B2 (ja) 2017-05-18 2023-07-20 アーペーセー エウローペ ソシエダッド リミタダ ウニペルソナル ヒト及びコンパニオン動物の認知欠損障害の治療に使用するための動物血漿又はその画分

Also Published As

Publication number Publication date
EP1463527A2 (en) 2004-10-06
MXPA04003156A (es) 2005-01-25
WO2003028668A2 (en) 2003-04-10
US20030099635A1 (en) 2003-05-29
EP1463527A4 (en) 2005-05-11
WO2003028668A3 (en) 2004-07-22
CA2462682A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US20030099635A1 (en) Use of oral gammaglobulin for the treatment of immune-mediated diseases
TWI537000B (zh) 治療性疫苗
US6187309B1 (en) Method for treatment of symptoms of central nervous system disorders
US8968735B2 (en) Compositions and methods including a recombinant human MAB that promotes CNS remyelination
US6713058B2 (en) Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US11098114B2 (en) Ovine derived human TNFα polyclonal antibody composition for oral administration
US6200565B1 (en) Oral administration of immunoglobulins for treating autoimmune hearing loss
AU2002348464A1 (en) Gammaglobulin treatment of immune disorders
US20040171553A1 (en) Peptides fragments of colostrinin and their use
WO2006036213A2 (en) The use of gammaglobulin for the treatment of periodontal disease
CA2473754C (en) Treatment of ms with goat serum
JP2004525077A (ja) イムノグロブリンｇ強化血漿画分の経口投与による免疫媒介性疾病の治療
WO2000062806A1 (en) Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051003

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20051130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090716